PATIENTS FOR AFFORDABLE DRUGS NOW (EIN 823044855) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2017

Legal Domicile

Principal Officer

DAVID MITCHEL

Phone

2027347555

Tax Period

2023-01-01 to 2023-12-31

PATIENTS FOR AFFORDABLE DRUGS NOW, founded in 2017, is a community nonprofit that reported $4.1M in total revenue in fiscal year 2023. Revenue surged 89% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.4M, a strong 35% operating margin.

Mission

PATIENTS FOR AFFORDABLE DRUGS NOW WORKS AT THE COMMUNITY, STATE, AND FEDERAL LEVELS TO MOBILIZE PATIENTS TO SUPPORT LEGISLATION TO LOWER DRUG PRICES. IT ALSO ENGAGES IN A LIMITED NUMBER OF ELECTORAL CAMPAIGNS TO ELEVATE THE ISSUE OF HIGH DRUG PRICES IN POLITICAL DEBATE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $4,060,198

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $4,060,198

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $2,165,542

Other Expenses $2,629,260

TOTAL EXPENSES $2,629,260

Year-over-Year Comparison

	2023	2022	Change
Revenue	$4,060,198	$2,147,206	+0.9%
Expenses	$2,629,260	$2,562,422	+0.0%
Net Income	$1,430,938	$-415,216	-4.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DAVID MITCHELL	FOUNDER/PRESIDENT	20	Officer Director	$0	$0	$0
GLORIA JOHNSON-CUSACK	BOARD MEMBER	0.25	Director	$0	$0	$0
ROBERT JONES	BOARD MEMBER	0.25	Director	$0	$0	$0
MERITH BASEY	EXECUTIVE DIRECTOR	40	Officer	$0	$0	$0
WENDY CHEW	CFO/COO	40	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$4,060,198	$2,629,260	$2,152,288	$1,430,938
2022	$2,147,206	$2,562,422	$187,355	$-415,216
2021	$11,760,456	$12,951,187	$750,404	$-1,190,731
2020	$3,930,935	$2,697,080	$1,834,948	$1,233,855
2019	$9,454,842	$9,128,736	$385,259	$326,106
2018	$937,875	$1,115,497	$127,110	$-177,622

PATIENTS FOR AFFORDABLE DRUGS NOW